PD37-03 ANDROGEN DEPRIVATION THERAPY AND THE INCIDENCE OF AUTOIMMUNE DISEASES IN 17,168 PATIENTS WITH PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II1 Apr 2017PD37-03 ANDROGEN DEPRIVATION THERAPY AND THE INCIDENCE OF AUTOIMMUNE DISEASES IN 17,168 PATIENTS WITH PROSTATE CANCER Jui-Ming Liu, Heng-Chang Chuang, Chun-Te Wu, and Ren-Jun Hsu Jui-Ming LiuJui-Ming Liu More articles by this author , Heng-Chang ChuangHeng-Chang Chuang More articles by this author , Chun-Te WuChun-Te Wu More articles by this author , and Ren-Jun HsuRen-Jun Hsu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1565AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Androgen deprivation therapy (ADT) has been the mainstay treatment for advanced prostate cancer for more than seven decades. However, the relationship between ADT and the incidence of autoimmune diseases remains unclear. METHODS A population-based nationwide cohort study of 17,168 patients diagnosed with prostate cancer between 1996 and 2013 was identified from the Taiwan National Health Insurance Research Database (NHIRD). Incident autoimmune diseases were ascertained at least 180 days after prostate cancer diagnosis. We used 1:1 propensity score–matched analysis ,multivariable-adjusted Cox proportional hazards models to investigate the association between ADT use and the risk of autoimmune diseases RESULTS Of the 17,168 selected prostate cancer patients, 16,379 patients were met our inclusion and exclusion criteria, with 7,025 receiving ADT and 9,354 were no-ADT users. After 1:1 propensity score matching, there were 5,590 ADT users and 5,590 non-ADT users in the study cohort. During a mean follow-up period of 5.1 years, 457 patients were newly diagnosed with autoimmune diseases with 155 among ADT users and 302 among non-ADT users. Kaplan-Meier curves demonstrated a higher cumulative probability of remaining autoimmune diseases-free among ADT users (Figure 1). Compared to non-ADT users, ADT group was statistically associated with a decreased risk of autoimmune diseases (adjusted hazard ratio (HR) 0.63, 95%CI 0.52-0.76) after Cox proportional hazards models. More specially, ADT users had a decreased risk of Graves' disease (aHR 0.46, 95%CI 0.23-0.91), psoriasis (aHR 0.53, 95%CI 0.29-0.97), type 1 diabetes (aHR 0.33, 95%CI 0.17-0.63), and uveitis (aHR 0.51, 95%CI 0.26-0.97) (Table 1). CONCLUSIONS The result of this study indicated that ADT use in patients with prostate cancer may decrease the risk of autoimmune diseases, especially in Graves' disease, psoriasis, type 1 diabetes, and uveitis. Further studies are warranted to further investigation to obtain a better understanding between ADT and autoimmune diseases. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e674-e675 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Jui-Ming Liu More articles by this author Heng-Chang Chuang More articles by this author Chun-Te Wu More articles by this author Ren-Jun Hsu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...